60,000

Patients living with ALS in the US, EU and Japan

20,000

New patients diagnosed and the number who die every year

100

Percent of ALS cases that are fatal

3

Mean years survival after symptom onset

ZERO

Number of approved drugs that cure ALS

Together we can improve the numbers

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s Disease or Motor Neurone Disease (MND) is a rapidly progressive and always fatal neurological disease. It was first diagnosed in 1874 by French neurologist Jean-Martin Charcot but despite more than 140 years of research, there is no cure and no effective treatment available.

2N Pharma is a small biotech company with a new approach to treating ALS which we believe will herald a paradigm shift in the fundamental understanding of the etiology and development of the disease. The company is based on a decade of research that has shown that it is possible to treat several neurological disorders, including ALS, by addressing a particular shared pathogenic mechanism.

Our mission is now to translate research into drugs that will make a truly positive difference for patients with ALS and other neurological disorders.

Other Indications

While our primary focus is ALS, we have pre-clinical data that strongly indicates that other neurological disorders share the same pathogenic mechanism and can be treated by the same or similar drugs. As we develop optimised versions of our drug candidates, we plan to test them in models of ALS, Huntington’s Disease, Parkinson’s Disease and Secondary Progressive Multiple Sclerosis (SPMS).

Incorporation

2N Pharma AB was incorporated in Sweden today to build on a decade of John Nieland’s research in neurological disorders. This marks the formal beginning

Read More »